Preview

Современная ревматология

Расширенный поиск

Длительное применение препарата бонвива для лечения постменопаузального остеопороза: новые данные

https://doi.org/10.14412/1996-7012-2012-717

Полный текст:

Аннотация

Остеопороз является заболеванием, имеющим большое социальное значение. Его лечение представляет собой сложную задачу и сопряжено с проблемой низкой приверженности пациентов приему препаратов и риском побочных эффектов. Ибандронат относится к группе бисфосфонатов. Проведенные исследования доказали эффективность двух его лекарственных форм (1 таблетка 1 раз в месяц и внутривенная инъекция 1 раз в 3 мес) в отношении снижения риска переломов костей. В настоящее время получены данные исследований длительной терапии этим препаратом, которые демонстрируют его благоприятное влияние на минеральную плотность костной ткани и маркеры костного метаболизма. Кроме того, показана высокая безопасность препарата при длительном использовании.

Литература

1. <div><p>Клинические рекомендации по диагностике, лечению и профилактике остеопороза. М., 2008; 176 с.</p><p>Cramer J.A., Gold D.T., Silverman S.L. et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteopor Int 2007; 18: 1023—103.</p><p>Landfeldt E., Strom O., Robbins S. et al. Adherence to treatment of primary osteoporosis and its association to fractures — the Swedish Adherence Register Analysis (SARA). Osteopor Int (in press).</p><p>Emkey R., Koltun W., Beusterien K. et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005; 21(12): 1895—903.</p><p>Hadji P., Minne H., Pfeifer M. et al. Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II). Joint Bone Spine 2007; 75(3): 303—10.</p><p>Cooper A., Drake J., Brankin E. Investigators PERSIST (2006) Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 60: 896—905.</p><p>Barrett J., Worth E., Bauss F. Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 2004; 44: 951—65.</p><p>Dando T.M., Noble S. Once-monthly ibandronate. Treat Endocrin 2005; 4(6): 381—7.</p><p>Croom K.F., Scott L.J. Intravenous ibandronate: in the treatment of osteoporosis. Drugs 2006; 66(12): 1593—601.</p><p>Russell R.G., Watts N.B., Ebetino F.H. et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteopor Int 2008; 19(6): 732—59.</p><p>Chesnut 3rd C.H., Skag A., Christiansen C. et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19(8): 1241 —9.</p><p>Bachmann G., Barr C.E., Gass M. Ibandronate reduces fracture rates in patients younger than 60 years with low lumbar spine bone mineral density. Obstet Gynecol 2006; 107(Suppl. 4): 82—3.</p><p>Felsenberg D., Miller P., Armbrecht G. et al. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. Bone 2005; 37(5): 651—4.</p><p>Miller P.D., McClung M.R., Macovei L. et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005; 20(8): 1315—22.</p><p>Reginster J.Y., Adami S., Lakatos P. et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: year results from the MOBILE study. Ann Rheum Dis 2006; 65(5): 654—61.</p><p>Miller P.D., Epstein S., Sedarati F. et al. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin 2008; 24(1): 207—13.</p><p>Stakkestad J.A., Lakatos P., Lorenc R. et al. Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. Clin Rheum 2008; 27(8): 955—60.</p><p>Delmas P.D., Adami S., Strugala C. et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthr Rheum 2006; 54(6): 1838—46.</p><p>Eisman J.A., Civitelli R., Adami S. et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheum 2008; 35(3): 488—97.</p><p>Recknor C., Lillestol M., Grant R. et al. Quarterly intravenous ibandronate injections provide continuing benefits in women with postmenopausal osteoporosis: DIVA study long-term extension [abstract no. W363]. J Bone Miner Res 2007; 22(Suppl. 1): 453.</p><p>Bianchi G., Garcia-Hernandez P., Grant R. et al. The DIVA study long-term extension: maintained efficacy with quarterly intravenous ibandronate injection [abstr no. SAT0292]. 2007 Annual European Congress of Rheumatology 2007 Jun 13—16, Barcelona.</p><p>Emkey R., Chesnut 3rd C.H., Schimmer R.C. et al. Benefits of oral ibandronate on non-vertebral fracture risk in postmenopausal osteoporosis: further analyses from a pivotal phase III study [abstract no. T389]. J Bone Miner Res 2007; 22(Suppl. 1): S329.</p><p>Geusens P. Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment. Curr Osteopor Rep 2009; 7: 12—7.</p><p>Bone H.G., Hosking D., Devogelaer J.-P. et al. Alendronate Phase III Osteoporosis Treatment Study Group Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350: 1189—99.</p><p>Mellstrom D.D., Sorensen O.H., Goemaere S. et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 75: 462—8.</p><p>Black D., Reid I., Cauley J. et al. The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: a randomized extension to the HORIZON Pivotal Fracture Trial (PFT). J Bone Miner Res 2010; 25(Suppl. 1): 1070. Available at http://www.asbmr.org/Meetings/AnnualMeet ing/AbstractDetail.aspx?aid=4781a020-dc3a-46be-b49d-f706b5509c4eAcces 13 Jan 2011.</p><p>Reginster J.-Y., Rabenda V. Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. Clin Interv Aging, 2006; 1: 415—23.</p><p>Reginster J.Y., Adami S., Lakatos P. et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: year results from the MOBILE study. Ann Rheum Dis 2006; 65: 654—61.</p><p>Miller P.D., Recker R.R., Reginster J.Y. et al. Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE longterm extension study. Osteopor Int 2011 [Epub ahead of print].</p><p>Delmas P.D., Adami S., Strugala C. et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthr Rheum 2006; 54: 1838—46.</p><p>Bianchi G., Czerwinski E., Kenwright A. et al. Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study longterm extension. Osteopor Int 2011 [Epub ahead of print].</p><p>Garnero P., Borel O., Delmas P.D. Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 2001; 47: 694—702.</p><p>Garnero P., Vergnaud P., Hoyle N. Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem 2008; 54: 188—96.</p></div><br />


Для цитирования:


Ершова О.Б., Белова К.Ю., Назарова А.В. Длительное применение препарата бонвива для лечения постменопаузального остеопороза: новые данные. Современная ревматология. 2012;6(1):57-60. https://doi.org/10.14412/1996-7012-2012-717

For citation:


Yershova O.B., Belova K.Yu., Nazarova A.V. Long-term use of Bonviva for the treatment of postmenopausal osteoporosis: new evidence. Modern Rheumatology Journal. 2012;6(1):57-60. (In Russ.) https://doi.org/10.14412/1996-7012-2012-717

Просмотров: 1052


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)